A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study

Table 4 Response

	All patients		Measurable disease at trial initiation		Elevated CA125
	Group A N= 96	Group B N= 93	Group A N= 79	Group B N= 80	Group A N= 17	Group B N= 13
CR	33 (34)	21 (23)	24 (30)	17 (21)	9 (53)	4 (31)
PR	23 (24)	26 (28)	22 (28)	24 (30)	1 (6)	2 (15)
OR	55 (57)	47 (51)	46 (58)	41 (51)	10 (59)	6 (46)
SD	16 (17)	15 (16)	15 (19)	14 (18)	1 (6)	1 (8)
PD	9 (9)	10 (11)	7 (9)	8 (10)	2 (12)	2 (15)
Early Tumor death	0 (0)	3 (3)	0 (0)	3 (4)	0 (0)	0 (0)
Treatment discontinuation prior to evaluation	4 (4)	6 (6)	2 (3)	6 (8)	2 (12)	0 (0)
NA*	17 (18)	6 (6)	9 (11)	8 (10)	2 (12)	4 (31)

*NA (not assessed): in case of measurable disease no computed tomography scans after treatment; in case of CA125 elevation no CA125 value after treatment.
There were no significant differences in any of the rates between the two groups; more specifically, the rates of CR (complete response), PR (partial responbse) and OR (overall response) were as follows:
All patients: (P = 0.072, 0.619 and 0.309, respectively).
Patients with measurable disease: (P = 0.208, 0.861 and 0.427, respectively).
Patients with evaluable disease (elevated CA125 and/or effusions): (P = 0.283, 0.565 and 0.713, respectively)

ISSN: 1741-7015